The role of community-based longitudinal studies in evaluating treatment effects. Example: benign prostatic hyperplasia.

Medical care

Volumn 33, Issue 4 Suppl, 1995, Pages

  Guess, H A ^a   Jacobsen, S J ^a   Girman, C J ^a   Oesterling, J E ^a   Chute, C G ^a   Panser, L A ^a   Lieber, M M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEALTH CARE PLANNING; HUMAN; INFORMATION PROCESSING; LONGITUDINAL STUDY; MALE; METHODOLOGY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNITED STATES;

COMMUNITY HEALTH PLANNING; DATA COLLECTION; FINASTERIDE; HUMANS; LONGITUDINAL STUDIES; MALE; MINNESOTA; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ACCEPTANCE OF HEALTH CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0345361780     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)